B-cell receptor recognizing Haemophilus influenzae type b polysaccharide (BCR-Hib-PRP)

The B-cell receptor (BCR) recognizing Haemophilus influenzae type b (Hib) polysaccharide is a specialized membrane-bound immunoglobulin essential for the adaptive immune defense against invasive bacterial infections. This receptor specifically targets polyribosylribitol phosphate (PRP), which constitutes the outer capsule of the Hib bacterium and serves as a major virulence factor by inhibiting phagocytosis (CDC, 2022). When the BCR binds to PRP, particularly when presented as a protein-conjugated antigen in vaccines, it triggers a cascade of signaling events that lead to B-cell maturation and the production of protective IgG antibodies (PubMed, PMID: 12433305). These antibodies are essential for opsonizing the bacteria, thereby facilitating their clearance by the immune system. The interaction between the BCR and Hib antigens is the fundamental mechanism behind the success of Hib conjugate vaccines, which have drastically reduced the incidence of Hib-related meningitis and pneumonia worldwide (WHO, 2019). Understanding the specificity and affinity of this receptor is crucial for the development of next-generation vaccines and for monitoring population-level immunity.

Other names

Hib-specific B-cell receptorAnti-PRP B-cell receptorPolyribosylribitol phosphate-specific B-cell receptorHaemophilus influenzae type b B-cell receptor

The B-cell receptor binds specifically to the polyribosylribitol phosphate (PRP) polysaccharide or its protein-conjugated form, initiating signal transduction that leads to B-cell activation, proliferation, and differentiation into plasma cells that secrete high-affinity anti-PRP antibodies (PubMed, PMID: 12433305).